ASTech Co., Ltd. (KOSDAQ:453860)
South Korea · Delayed Price · Currency is KRW 7,090.00
0.00 (0.00%)
At close: Oct 8, 2026
ASTech Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 19,459 | 24,560 | 42,572 | 47,339 | 32,164 | 14,646 |
Revenue Growth | -34.68% | -42.31% | -10.07% | 47.18% | 119.61% | 63.63% |
Gross Profit Gross Profit Growth | -3,882 | 4,190 | 13,449 | 13,602 | 7,467 | 2,922 |
Operating Income Operating Income Growth | -8,339 | -110.16 | 8,702 | 9,180 | 4,522 | 745.83 |
Net Income Net Income Growth | -6,692 | 2,152 | 9,485 | 6,822 | 1,840 | 517.76 |
Earnings Per Share EPS Growth | -1117.30 | 374.00 | 1623.00 | 1543.00 | 258939.57 | 58823.46 |
EPS Growth | - | -76.96% | 5.18% | -99.40% | 340.20% | -1.82% |
| Fiscal Year | FY 2024 | FY 2023 |
|---|---|---|
| Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
Ultraviolet Screening Material Ultraviolet Screening Material Growth | 34,642 | 38,532 |
Clopidogrel Camphorsulphonic Acid Clopidogrel Camphorsulphonic Acid Growth | 4,995 | 6,845 |
Other Other Growth | 2,935 | 1,962 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 13,435 | 6,776 | 13,168 | 22,045 | 324.2 | 1,331 |
Total Debt Total Debt Growth | 42,946 | 41,564 | 29,602 | 15,804 | 20,647 | 19,274 |
Net Cash (Debt) Net Cash Growth | -29,511 | -34,788 | -16,434 | 6,241 | -20,323 | -17,943 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -4927.35 | -6043.30 | -2812.19 | 1411.49 | -2860775.02 | -2038512.97 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -1,811 | 2,893 | 12,431 | 7,069 | -2,711 | 3,134 |
Capital Expenditures CapEx Growth | -15,898 | -30,935 | -35,128 | -9,144 | -696.7 | -16,550 |
Free Cash Flow Free Cash Flow Growth | -17,709 | -28,042 | -22,697 | -2,074 | -3,408 | -13,416 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | -19.95% | 17.06% | 31.59% | 28.73% | 23.22% | 19.95% |
Operating Margin | -42.86% | -0.45% | 20.44% | 19.39% | 14.06% | 5.09% |
Pretax Margin | -43.87% | 0.69% | 22.06% | 16.54% | 5.51% | 1.82% |
Profit Margin | -34.39% | 8.76% | 22.28% | 14.41% | 5.72% | 3.54% |
FCF Margin | -91.01% | -114.18% | -53.32% | -4.38% | -10.60% | -91.61% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Oct '26 Oct 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | 42.34 | 11.22 | 29.02 | - | - |
Forward PE | - | 8.80 | 9.25 | - | - | - |
PS Ratio | 2.06 | 3.71 | 2.50 | 4.18 | - | - |